Mark Bodenrader compensation by year
Cerevel Therapeutics Summary Compensation Table · all 2 fiscal years held| Component | FY2021 | FY2022 |
|---|---|---|
| Salary | $308,851 | $337,712 |
| Bonus | $0 | $0 |
| Stock awards | $0 | $499,994 |
| Option awards | $872,100 | $587,480 |
| Non-equity incentive | $114,643 | $140,154 |
| Pension and deferred compensation | $0 | $0 |
| All other | $17,400 | $18,300 |
| Total | $1,312,994 | $1,583,640 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cerevel Therapeutics Holdings, Inc. DEF 14A filed April 28, 2023, accession 0000950170-23-015766, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Cerevel Therapeutics Holdings, Inc. filed document, accession 0000950170-23-015766. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 18,932 | $597,115 | — |
| Option | 10,907 | — | $3.50 |
| Option | 48,750 | — | $12.70 |
| Option | 24,800 | — | $30.36 |
| Option | 32,723 | — | $9.88 |
| Option | 3,636 | — | $10.28 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Cerevel Therapeutics Holdings, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
12 Form 4 lines since the FY2022 proxy (filed April 28, 2023)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2024-08-01 | Disposition to the issuer | — | 17,724 | — | 0 |
| 2024-08-01 | Disposition to the issuer derivative | — | 277,817 | — | 0 |
| 2024-08-01 | Disposition to the issuer derivative | — | 24,852 | $0.00 | 0 |
| 2024-01-19 | Grant or award derivative | — | 24,852 | $0.00 | 24,852 |
| 2023-12-20 | Sale | — | 7,889 | $41.42 | 17,724 |
| 2023-12-19 | Exercise or conversion | — | 14,199 | — | 20,528 |
| 2023-12-19 | Exercise or conversion | — | 5,085 | — | 25,613 |
| 2023-12-19 | Exercise or conversion derivative | — | 14,199 | $0.00 | 0 |
The 8 most recent of 12 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Cerevel Therapeutics discloses, by trigger · FY2022| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $270,000 | $0 | $17,413 | $287,413 |
| Change in control and involuntary termination | $351,611 | $2,636,743 | $17,413 | $3,005,767 |
Per the Potential Payments Upon Termination or Change in Control table in Cerevel Therapeutics Holdings, Inc.'s FY2022 proxy. Estimates as the company printed them; a dash means it printed no figure.
Cerevel Therapeutics’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| N. Anthony Coles | Chief Executive Officer and Chairperson of the Board of Directors | $11,225,426 |
| Raymond Sanchez | Chief Medical Officer | $4,805,110 |
| John Renger | Chief Scientific Officer | $4,779,729 |
| Abraham Ceesay | President | $3,676,491 |
| Mark Bodenrader · this page | Interim Chief Financial Officer; Senior Vice President, Finance and Chief Accounting Officer | $1,583,640 |
The full Cerevel Therapeutics compensation record
free company briefThis page is one person within Cerevel Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Cerevel Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cerevel Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.